K2SPIRITNCT06646978
Long-term Risk of Second Primary Malignancies for Chronic Myeloid Leukaemia in the French Imatinib-based SPIRIT Trial
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Minor Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Enrolling by Invitation
- Study First Submitted
- Minor: routine updates
Endpoints
Primary
Risk of second primary malignancies (SPM)
Timeframe: Through study completion, an average of 20 years
Secondary (1)
Treatment strategies for CML and SPM at their occurrence
Arms and interventions
Patients with chronic myeloid leukaemia included in the French imatinib-based SPIRIT trial
Drugs: Imatinib (STI571)
Sites
1 site in 1 country
- CHU de PoitiersPoitiers, France